Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

COCP vs STTK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STTK Captures Overall Composite Edge (51.1 HOLD vs 47.1 HOLD), While COCP Leads 3–2 on Growth & Valuation Pillars

STTK Overall Winner 6-Pillar Tally: COCP 3 – 2 STTK (1 Tie) Matrix Metrics: COCP 2 – 5 STTK

As of Nov 16, 2026, Shattuck Labs, Inc. (STTK) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (51.1/100 HOLD vs. 47.1/100 HOLD) after splitting the core matrix 5–2 (led by Profitability & Quality, Options & Positioning), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. COCP trades at $1.00 (N/M Forward P/E, -3063.6% operating margin) versus STTK at $4.56 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: STTK earns the overall head-to-head edge with a stronger Unified Composite Score (51.1/100 HOLD vs. COCP 47.1/100 HOLD) and 1.48β · 78% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3); meanwhile STTK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About COCP vs STTK
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
TTM Revenue $330,000
Forward P/E N/M
Beta / 30D Vol 1.04β · 54% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $1.00 · SMA50: $1.08
STTK NASDAQ Head-to-Head Winner
Shattuck Labs, Inc. Common Stock
Pharmaceutical Preparations
$4.56
-1.94% 1D
Market Cap $474.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.48β · 78% Vol
Unified Composite Score
51.1 / 100 HOLD
Tech 48.0 Fund 58.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.8%), weak momentum, RSI 36
RSI-14: 36.1 · SMA20: $5.24 · SMA50: $5.75

6-Pillar Scorecard Institutional Category Breakdown (COCP 3 – 2 STTK)

Columns: Metric · COCP · STTK
1. Valuation Multiples COCP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 49.7x N/M
2. Growth & Scale COCP
Revenue Growth (YoY) +26.9% -66.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $330,000 N/A
Market Cap $19.6M $474.6M
3. Profitability & Quality STTK
Gross Margin N/A N/A
Operating Margin -3063.6% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -311.7% -47.2%
4. Balance Sheet & Cash Flow COCP
Cash Generation (TTM) -$7.6M -$50M
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.3M Net Cash $59M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning STTK
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 72.4% (10th %ile)
Put/Call OI Skew N/A 4.54x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: COCP (2) vs STTK (5)
Institutional Metric COCP STTK Criterion Row Edge
Market Capitalization
Scale
$19.6M $474.6M Larger Scale STTK
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+26.9% -66.6% Higher Growth COCP
Operating Margin (TTM)
Profitability
-3063.6% 0.0% Higher Margin STTK
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-311.7% -47.2% Higher ROE STTK
52-Week Range Position
Momentum
19% ($1–$2) 43% ($2–$8) Stronger Trend STTK
Beta / 30D Volatility
Risk Regime
1.04β · 54% Vol 1.48β · 78% Vol Lower Realized Risk COCP
Unified Institutional Score
Composite Signal
47.1 / 100 (HOLD) 51.1 / 100 (HOLD) Higher Composite STTK
Trailing 12M Revenue (USD)
Operating Scale
$330,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 49.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.6M ($3.3M Net Cash) -$50M ($59M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCP +13.86 pp
COCP: -2.01% · STTK: -15.87%
3M Horizon COCP +31.34 pp
COCP: -7.45% · STTK: -38.79%
6M Horizon COCP +8.32 pp
COCP: -15.3% · STTK: -23.62%
1Y Horizon STTK +150.79 pp
COCP: -2.96% · STTK: +147.83%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period COCP Revenue STTK Revenue COCP Op. Margin STTK Op. Margin Margin Leader
FY2011 $10M N/A -30.6% N/A COCP
FY2019 $10M $10M -737.4% -253.5% STTK
FY2020 $0M $10M -476.0% -371.8% STTK
FY2021 N/A $30M N/A -150.8% STTK
FY2022 N/A $0M N/A -15848.0% STTK
FY2023 N/A $0M N/A -5549.6% STTK
FY2024 N/A $10M N/A -1408.3% STTK
FY2025 N/A $0M N/A -5150.8% STTK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
COCP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STTK BREAKDOWN
58d in phase · OBV NEUTRAL
Current IV 72.4%
IV Percentile 10th %ile
Put/Call OI Skew 4.54x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact STTK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
COCP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $19.6M market capitalization and -3063.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STTK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $474.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ COCP vs STTK Key Questions & Quantitative Answers

As of Nov 16, 2026, Shattuck Labs, Inc. (STTK) captures the overall head-to-head institutional edge over Cocrystal Pharma, Inc. (COCP) on higher Unified Composite conviction (51.1/100 HOLD vs. 47.1/100 HOLD) after splitting the core matrix 5–2 (led by Profitability & Quality, Options & Positioning), while COCP wins 3–2 across the 6-pillar growth and valuation breakdown. COCP trades at $1.00 (N/M Forward P/E, -3063.6% operating margin) versus STTK at $4.56 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: STTK earns the overall head-to-head edge with a stronger Unified Composite Score (51.1/100 HOLD vs. COCP 47.1/100 HOLD) and 1.48β · 78% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3); meanwhile STTK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

COCP leads the Growth & Scale pillar: COCP posts +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin), compared with STTK at -66.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2011 to FY2025), COCP cumulative revenue shifted +0.0% while STTK shifted +0.0%. In operating R&D and SG&A reinvestment, COCP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STTK.

COCP screens cheaper on headline valuation multiples. COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin), whereas STTK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCP (-311.7% ROE) versus STTK (-47.2% ROE) capital efficiency.

In options market volatility and institutional positioning, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 54% Vol realized risk). By comparison, STTK carries 72.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 4.54x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.48β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.